Payment overview · 2025
General Payments
$351.95
17 reported records · 9 companies
Healthcare provider profile · identity verified
Denise A Abselet, DO
Allopathic & Osteopathic Physicians|Internal Medicine · PORT JEFFERSON STATION, NY · NPI 1780770131
Verified facts
What the public records show
CMS Open Payments records show Denise A Abselet, DO received $351.95 in general payments during 2025 across 17 reported records.
Amgen Inc. accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Gemtesa, Jardiance, Mounjaro, Shingrix.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $109.75 | 31.2% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $88.94 | 25.3% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.14 | 7.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.02 | 7.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.16 | 6.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.46 | 6.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.77 | 5.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.12 | 5.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.59 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $351.95 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $109.75 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $91.32 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $88.94 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.14 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.02 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 39 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 16 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 16 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
39 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
232 | 42 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 703 | 212 |
| Levothyroxine Sodium | Levothyroxine Sodium | 600 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 575 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 515 | 166 |
| Metoprolol Succinate | Metoprolol Succinate | 449 | 116 |
| Losartan Potassium | Losartan Potassium | 388 | 117 |
| Omeprazole | Omeprazole | 367 | 114 |
| Potassium Chloride | Potassium Chloride | 342 | 60 |
| Furosemide | Furosemide | 287 | 63 |
| Sertraline Hcl | Sertraline Hcl | 281 | 64 |
| Eliquis | Apixaban | 232 | 42 |
| Famotidine | Famotidine | 198 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 52 |
| Alprazolam | Alprazolam | 175 | 73 |
| Montelukast Sodium | Montelukast Sodium | 168 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 163 | 39 |
| Metformin Hcl | Metformin Hcl | 163 | 50 |
| Gabapentin | Gabapentin | 161 | 43 |
| Synthroid | Levothyroxine Sodium | 161 | 40 |
| Simvastatin | Simvastatin | 151 | 42 |
| Ezetimibe | Ezetimibe | 148 | 48 |
| Spironolactone | Spironolactone | 137 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 45 |
| Lisinopril | Lisinopril | 128 | 33 |
| Allopurinol | Allopurinol | 120 | 29 |
| Torsemide | Torsemide | 115 | 16 |
| Farxiga | Dapagliflozin Propanediol | 98 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 24 |
| Jardiance | Empagliflozin | 91 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 18 |
| Januvia | Sitagliptin Phosphate | 83 | 21 |
| Prednisone | Prednisone | 83 | 36 |
| Atenolol | Atenolol | 82 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 38 |
| Carvedilol | Carvedilol | 71 | 19 |
| Donepezil Hcl | Donepezil Hcl | 68 | 12 |
| Ozempic | Semaglutide | 67 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 17 |
| Metformin Hcl Er | Metformin Hcl | 66 | 22 |
| Finasteride | Finasteride | 64 | 15 |
| Cephalexin | Cephalexin | 60 | 41 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 16 |
| Amoxicillin | Amoxicillin | 55 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 14 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 14 |
| Bupropion Xl | Bupropion Hcl | 49 | 16 |
| Rybelsus | Semaglutide | 48 | 14 |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 16 |
| Hydrocortisone | Hydrocortisone | 44 | 11 |
| Methylprednisolone | Methylprednisolone | 43 | 40 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Lorazepam | Lorazepam | 41 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 37 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 39 | 39 |
| Digoxin | Digoxin | 39 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 12 |
| Irbesartan | Irbesartan | 38 | 12 |
| Meloxicam | Meloxicam | 38 | 18 |
| Ramipril | Ramipril | 37 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Nystatin | Nystatin | 34 | 14 |
| Gemtesa | Vibegron | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | 12 |
| Folic Acid | Folic Acid | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 11 |
| Valsartan | Valsartan | 30 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Timolol Maleate | Timolol Maleate | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 23 |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 15 |
| Verapamil Sr | Verapamil Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Travoprost | Travoprost | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Edarbi | Azilsartan Medoxomil | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $351.95 · 17 records | Amgen Inc. | ABRYSVO, AREXVY, COMIRNATY, Cologuard Collection Kit, GEMTESA, INSPIRE, JARDIANCE, LEQVIO, MOUNJARO, OTEZLA, PREVNAR 20, REPATHA, SHINGRIX, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error